The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model

Table 1 Serum urea concentration in different groups

Urea	zero time	1st week	2nd week	3rd week 1st dose of CMSCs	4th week	5th week 2nd dose of CMSCs	6th week	8th week	10th week	12th week
G1 (CKD)	13.33 ± 1.2	34 ± 2.08	43.66 ± 2.4	49.33 ± 2.9	60.33 ± 2.6	60 ± 2.88	64 ± 3.05	65.33 ± 2.9	67.66 ± 3.17	71 ± 3.78
G2 (camel WJ-MSCs)	12.33 ± 1.45	36.33 ± 1.76	43 ± 1.52	55 ± 2.88	38 ± 1.52*	37.33 ± 1.76*	34.66 ± 0.88*	33.33 ± 1.6*	27.66 ± 1.45*	26.6 ± 1.76*

Data are presented as mean value ± SE. * indicates significant difference at P value < 0.05

ISSN: 1757-6512